| 产品编号 | bsm-63033R |
| 英文名称 | Rabbit Anti-CD163 antibody |
| 中文名称 | CD163重组兔单抗 |
| 别 名 | Scavenger receptor cysteine-rich type 1 protein M130; CD 163; CD163 antigen; CD163 molecule; Hemoglobin Scavenger Receptor; M130; M130 antigen precursor; Macrophage associated antigen; MM130; C163A_HUMAN. |
| 抗体来源 | Rabbit |
| 克隆类型 | Recombinant |
| 克 隆 号 | 11C9 |
| 交叉反应 | Human |
| 产品应用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 125kDa |
| 检测分子量 | 150 |
| 细胞定位 | 细胞膜 分泌型蛋白 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CD163 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
The protein encoded by this gene is a member of the scavenger receptor cysteine-rich (SRCR) superfamily, and is exclusively expressed in monocytes and macrophages. It functions as an acute phase-regulated receptor involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages, and may thereby protect tissues from free hemoglobin-mediated oxidative damage. This protein may also function as an innate immune sensor for bacteria and inducer of local inflammation. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Aug 2011] Function: Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells. Subcellular Location: Secreted and Cell membrane. Isoform 1 and isoform 2 show a lower surface expression when expressed in cells. Tissue Specificity: Expressed in monocytes and mature macrophages such as Kupffer cells in the liver, red pulp macrophages in the spleen, cortical macrophages in the thymus, resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood. Post-translational modifications: A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide, phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3, and thus probably induced by membrane-bound metalloproteinases ADAMs. Phosphorylated. Similarity: Contains 9 SRCR domains. SWISS: Q86VB7 Gene ID: 9332 Database links: CD163是SRCR超家族成员之一，又称为血红蛋白清道夫受体（hemoglobin scavenger receptor, HbSR）、M130或p155。CD163的表达水平受很多因素调节，糖皮质激素及抗炎介质如IL-10以及IL-6能上调CD163, 而促炎介质如脂多糖（lipopolysaccharide, LPS）、γ-干扰素（interferon-γ， IFN-γ）以及TNF-α则抑制CD163表达。 CD163是一种I型膜蛋白，又称为M130抗原、Ber-Mac3、Ki-M8或SM4。CD163限制性表达于单核/巨噬细胞系，所有循环系统的单核细胞和大多数组织（除外淋巴滤泡套区和生发中心）的巨噬细胞均阳性表达，主要用于单核/巨噬细胞的检测。 |
| 产品图片 |
Paraformaldehyde-fixed, paraffin embedded Human Placenta; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD163 Monoclonal Antibody, Unconjugated(bsm-63033R) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023)and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Liver; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD163 Monoclonal Antibody, Unconjugated(bsm-63033R) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023)and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD163 Monoclonal Antibody, Unconjugated(bsm-63033R) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023)and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Ovarian Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD163 Monoclonal Antibody, Unconjugated(bsm-63033R) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023)and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Colon Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD163 Monoclonal Antibody, Unconjugated(bsm-63033R) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023)and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Lung Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD163 Monoclonal Antibody, Unconjugated(bsm-63033R) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023)and DAB (C-0010) staining.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
